CHRO stock icon

Chromocell Therapeutics


About: Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.

Employees: 7

Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

65,994,700% more capital invested

Capital invested by funds: $0 [Q4 2023] → $660K (+$660K) [Q1 2024]

100% more funds holding

Funds holding: 0 [Q4 2023] → 1 (+1) [Q1 2024]

100% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 0

5.06% more ownership

Funds ownership: 0% [Q4 2023] → 5.06% (+5.06%) [Q1 2024]

Research analyst outlook

We haven’t received any recent analyst ratings for CHRO.

Financial journalist opinion